NUS

Nu Skin Enterprises, Inc. NUS posted second-quarter 2026 results, with top line missing the Zacks Consensus Estimate and the bottom line matching the same. Both net sales and earnings experienced year-over-year declines. In the second quarter, Nu Skin posted adjusted earnings of 20 cents per share. The metric declined 53.5% from adjusted earnings of 43 cents per share in the year-ago quarter. The bottom line matched the Zacks Consensus Estimate. Nu Skin Enterprises, Inc. price-consensus-eps-surprise-chart | Nu Skin Enterprises, Inc. Quote Quarterly revenues of $320.1 million tumbled 17.1% year over year. Revenues included a negative impact of 1% from foreign currency fluctuations. On a constant-currency basis, revenues fell 16.1%. Rhyz revenues fell 25% year over year to $48.9 million. NUS’s top line missed the Zacks Consensus Estimate of $345 million.Sales leaders were down 9% year over year to 26,998. Nu Skin’s customer base dropped 14% to 660,037. The company’s paid affiliates were down 8% to 120,291. Gross profit declined 17.8% year over year to $218.3 million. Gross margin contracted 60 basis points to 68.2%. Within the Nu Skin business, however, gross margin improved 20 basis points to 77.7% from 77.5% in the prior-year quarter.Selling expenses declined 15.8% to $107.9 million, but increased 50 basis points to 33.7% of revenues from 33.2%. Nu Skin business’ selling expenses were 39.8%, down 20 basis points from 40% in the prior-year quarter.General and administrative expenses fell 14.9% to $90.8 million, while rising 80 basis points to 28.4% of revenues from 27.6%. Adjusted operating income decreased 36.5% year over year to $19.6 million. The company’s adjusted operating margin decreased 190 basis points to 6.1% from 8% in the year-ago quarter. Region-wise, Nu Skin’s revenues declined 18.1%, 13.7%, 14.9%, 14.4%, 13.4%, 5.3%, 24.8% and 81.5% in the Americas, Mainland China, Southeast Asia/Pacific, Japan, Europe & Africa, Hong Kong/Taiwan, South Korea and Nu Skin Other, respectively. This Zacks Rank #3 (Hold) company ended the quarter with cash and cash equivalents of $189.6 million, long-term debt of $193.7 million and total stockholders' equity of $542.7 million. In the reported quarter, the company paid out dividends of $2.9 million and made no stock repurchases. The company has $137.3 million remaining under the current share repurchase authorization.Nu Skin announced a cash dividend of 6 cents per share, payable on Sept. 9, 2026, to its shareholders’ record as of Aug. 28. For 2026, NUS now expects revenues of $1.28 billion to $1.35 billion, compared with its previous outlook of $1.35 billion to $1.50 billion. The updated forecast implies a 9% to 14% year-over-year decline in revenues, including an approximately 1% unfavorable impact from foreign currency fluctuations. Adjusted EPS is now expected to range from 70 cents to 90 cents, down from the previously projected 80 cents to $1.20.For the third quarter, Nu Skin expects revenues of $310 million to $340 million, representing a year-over-year decline of 7% to 15%, including an approximate 2% to 3% negative impact from foreign exchange. Adjusted earnings are projected between 10 cents and 20 cents per share.NUS stock has fallen 21.4% in the past three months against the industry’s growth of 11.5%. Image Source: Zacks Investment Research The Estee Lauder Companies Inc. EL manufactures, markets and sells skin care, makeup, fragrance and hair care products worldwide. It currently has a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.The Zacks Consensus Estimate for Estee Lauder’s current fiscal-year sales and earnings calls for growth of 4.4% and 59.6%, respectively, from the year-ago reported numbers. EL delivered a trailing four-quarter average earnings surprise of 39.1%.Ulta Beauty, Inc. ULTA operates as a specialty beauty retailer in the United States. It currently holds a Zacks Rank #2. ULTA delivered a trailing four-quarter earnings surprise of 10%, on average.The Zacks Consensus Estimate for Ulta Beauty’s current fiscal-year sales and earnings calls for growth of 10.3% and 12.3%, respectively, from the year-ago reported numbers.Sally Beauty Holdings, Inc. SBH operates as a specialty retailer and distributor of professional beauty supplies. It currently carries a Zacks Rank of 2. Sally Beauty delivered a trailing four-quarter average earnings surprise of 6.4%.The Zacks Consensus Estimate for Sally Beauty’s current fiscal-year sales and earnings calls for growth of 0.8% and 9%, respectively, from the year-ago reported numbers. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nu Skin Enterprises, Inc. (NUS) : Free Stock Analysis Report The Estee Lauder Companies Inc. (EL) : Free Stock Analysis Report Ulta Beauty Inc. (ULTA) : Free Stock Analysis Report Sally Beauty Holdings, Inc. (SBH) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Nu Skin Enterprises, Inc.? Here are five stocks we like better. Nu Skin reported Q2 revenue of $320.1 million and adjusted EPS of $0.20, while reported EPS was negative $5.14 due primarily to a $78.9 million goodwill impairment and a $167.5 million deferred-tax valuation allowance. Adjusted operating margin fell to 6.1% from 8% year over year. The Prysm iO rollout gained traction, with more than 39,000 devices placed and 2.5 million scans completed. Management is shifting the platform’s focus toward scalable wellness consultations and plans to launch an AI-enabled app with personalized assessments and product recommendations. Nu Skin maintained full-year guidance for revenue of $1.28 billion to $1.35 billion and adjusted EPS of $0.70 to $0.90, while delaying its formal India launch to the first half of 2027. Organizational restructuring is expected to generate cost savings beginning in late 2026, but will require $5 million to $10 million in transition costs. 3 high yield stock ETFs that make any income portfolio better Nu Skin Enterprises (NYSE:NUS) reported second-quarter revenue of $320.1 million and adjusted earnings per share of $0.20, as the company continued the rollout of its Prysm iO wellness platform and pursued cost and margin initiatives. Reported earnings per share were negative $5.14 for the quarter, reflecting non-cash accounting charges related to goodwill impairment and a valuation allowance on U.S. deferred tax assets. Interim CFO Chelsea Lantz said the company recorded a $78.9 million non-cash goodwill impairment charge tied to its Rhyz manufacturing reporting unit, as well as a $167.5 million non-cash valuation allowance in income tax expense. → SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat 3 Mid Cap Dividend Growers Worth Buying “We have excluded these non-cash accounting adjustments from our adjusted results as we do not believe they are indicative of our ongoing operating performance,” Lantz said. Second-quarter revenue included an approximately 1%, or $4 million, foreign-currency headwind. Consolidated gross margin was 68.2%, compared with 68.8% a year earlier, which Lantz attributed to the revenue mix between Nu Skin’s core business and Rhyz businesses. → 3 Dividend Champion Utilities for a Market That Can't Sit Still Within the core Nu Skin business, gross margin improved 20 basis points year over year to 77.7%. Selling expense represented 33.7% of revenue, compared with 33.2% a year earlier. Core Nu Skin selling expense declined slightly to 39.8% of revenue from 40%. General and administrative expenses fell $15.9 million from the prior-year quarter, though they rose as a share of revenue to 28.4% from 27.6%. Adjusted operating margin was 6.1%, down from 8% in the previous year’s quarter. → Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War The company generated $10.6 million in operating cash flow during the quarter and ended the period with $189.6 million in cash and cash equivalents. Total debt stood at $213.7 million. Nu Skin returned $2.9 million to shareholders through dividends, did not repurchase shares during the period, and had $137.3 million remaining under its repurchase authorization. President and CEO Ryan Napierski said the company has placed more than 39,000 Prysm iO devices, up nearly 30% sequentially, and completed 2.5 million scans, up 25% from the comparable quarterly period. Nu Skin expects to have placed between 50,000 and 60,000 devices by year-end. Management said an early finding from the rollout was that sales leaders are using Prysm iO primarily as a wellness consultation tool rather than as an in-home device, which had been an earlier expectation. The company is adjusting its commercial strategy to help affiliates conduct wellness consultations at greater scale. At a global live event in Japan in September, Nu Skin plans to introduce an AI-enabled Prysm iO application powered by its Nu Intelligence platform. Napierski said the app is intended to provide personalized wellness assessments, product recommendations and 90-day wellness plans. Nu Skin also plans to introduce products aimed at women’s health needs, including products intended to support hormonal balance. The company said its ongoing research in epigenetics and biological aging is informing its “Aging Response Modulator” science approach. Napierski said recruiting and leadership development remain below the levels required for sustainable growth despite the resilience of the company’s field organization. Nu Skin is revising its global compensation framework to place greater emphasis on product selling, team building and leadership development, while retaining flexibility for local markets. The framework was rolled out across the Americas and Pacific markets during the first half of 2026 and is expected to expand into other markets through 2027. The company also plans to introduce a leadership achievement roadmap this fall, with clearer development pathways, recognition and incentives for sales leaders. Nu Skin is also moving toward an East-West operating model from its current structure of seven distinct regions. The transition, expected over the next two quarters, is designed to align resources with market needs and improve organizational agility and efficiency. Lantz said the changes are expected to produce cost savings beginning in the second half of 2026, with a larger benefit anticipated in 2027. The company expects $5 million to $10 million in cash-based organizational transition costs through the rest of the year; those costs are excluded from adjusted earnings guidance. Nu Skin pushed its formal India market opening into the first half of 2027 as it refines its business model, operational setup and field readiness. Napierski said India remains a long-term growth opportunity but requires further work on local manufacturing quality standards, logistics partnerships, technology integration and affiliate business-building practices. The company said it can currently facilitate business in India through products and network development, but it intends to optimize the model before its formal launch. For the third quarter, Nu Skin forecast revenue of $310 million to $340 million, including an expected 2% to 3% foreign-currency headwind. The company projected reported EPS of zero to $0.09 and adjusted EPS of $0.10 to $0.20. For the full year, Nu Skin now expects: Revenue of $1.28 billion to $1.35 billion, including an anticipated foreign-currency headwind of about 1%. Reported EPS of negative $4.90 to negative $4.73. Adjusted EPS of $0.70 to $0.90. The company said its adjusted outlook excludes certain first-quarter charges, the second-quarter goodwill impairment, anticipated organizational transition costs and the deferred tax valuation allowance. Its adjusted guidance assumes an effective tax rate of approximately 35%. Nu Skin Enterprises, Inc is a Utah-based direct selling company that develops and distributes personal care products and dietary supplements. Operating through a network marketing model, Nu Skin offers a portfolio of wellness, anti-aging skin care, hair care and nutritional products designed to support healthy living and appearance. The company leverages independent distributors to market its offerings directly to consumers across multiple channels, including online platforms and localized events. Founded in 1984 by Blake M. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Nu Skin Enterprises Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Nu Skin Enterprises (NUS) came out with quarterly earnings of $0.2 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this seller of skin care and nutritional products through a direct-selling model would post earnings of $0.15 per share when it actually produced earnings of $0.14, delivering a surprise of -6.67%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Nu Skin, which belongs to the Zacks Cosmetics industry, posted revenues of $320.11 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 7.27%. This compares to year-ago revenues of $386.14 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Nu Skin shares have lost about 42.9% since the beginning of the year versus the S&P 500's gain of 13.3%. While Nu Skin has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Nu Skin was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.32 on $375.5 million in revenues for the coming quarter and $1.00 on $1.43 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Cosmetics is currently in the top 23% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Estee Lauder (EL), is yet to report results for the quarter ended June 2026. The results are expected to be released on August 19. This beauty products company is expected to post quarterly earnings of $0.31 per share in its upcoming report, which represents a year-over-year change of +244.4%. The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. Estee Lauder's revenues are expected to be $3.55 billion, up 4.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nu Skin Enterprises, Inc. (NUS) : Free Stock Analysis Report The Estee Lauder Companies Inc. (EL) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management attributed Q2 performance to the ongoing global rollout of Prysm iO, which saw device placements increase nearly 30% quarter-over-quarter to 39,000 units. A key strategic shift occurred as management realized sales leaders are using Prysm iO primarily as a wellness consultation tool rather than the hypothesized in-home placement device. The company is transitioning to a distinct East-West organizational structure, moving away from a seven-region model to better support unique market dynamics and improve agility. Core Nu Skin gross margins improved to 77.7% through strategic price increases and supply chain efficiencies, despite overall margin pressure from the Rhyz business mix. Management acknowledged that recruiting and leadership development remain below levels required for sustainable growth, prompting a redesign of global compensation and incentive frameworks. Operational focus is shifting toward 'health span' and 'aging response modulator' science, integrating epigenetics into the next generation of anti-aging products. Full-year 2026 revenue guidance was updated to $1.28 to $1.35 billion, incorporating an anticipated 1% foreign currency headwind. The formal launch of the India market has been delayed to the first half of 2027 to optimize the business model and ensure regulatory and supply chain readiness. Management plans to introduce an AI-enabled Prysm iO app in September 2026 to deliver personalized 90-day wellness plans and improve customer lifetime value. The new East-West operating model is expected to generate meaningful cost savings starting in the second half of 2026, with larger benefits projected for 2027. Nu Skin targets a total of 50,000 to 60,000 Prysm iO device placements by the end of 2026, supported by a major global live event in Japan. Reported EPS was significantly impacted by a $78.9 million non-cash goodwill impairment charge related to the Rhyz manufacturing unit following changes in market capitalization. A $167.5 million non-cash valuation allowance was recorded against U.S. deferred tax assets, which management excluded from adjusted results. The company anticipates $5 to $10 million in cash-based organizational transition costs through the remainder of the year related to the East-West restructuring. Macroeconomic disruptions in Latin America and the learning curve for beauty-focused affiliates transitioning to wellness products remain persistent headwinds. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management explained the delay is intentional to ensure local manufacturing meets '6S Quality' standards and to integrate complex local logistics and government payment systems. The extra time will be used to refine the business model to better align with local commercial practices and network-building behaviors observed over the last seven months. Management noted a learning curve as beauty-oriented affiliates adapt to selling wellness technology, which contributed to the first-half results being below expectations. Long-term synergy is expected as the device allows affiliates to act as wellness consultants, expanding the potential customer base beyond traditional beauty products. Growth is expected to be driven by the September live event in Japan, which aims to align over 10,000 mid-to-high level leaders with the new AI and epigenetic strategy. The fourth quarter will also benefit from traditional holiday promotions and specific year-end sales incentives in Eastern markets.

PROVO, Utah, August 10, 2026--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter results. Executive Summary Q2 2026 vs. Prior-year Quarter "We continue to make progress toward our long-term strategy with the continued rollout of Prysm iO and preparations for the formal launch of India," said Ryan Napierski, Nu Skin president and CEO. "As these initiatives are taking hold, we are incorporating valuable learnings to strengthen our plans moving forward. At the same time, we are re-aligning our organizational resources to better position the business to drive sustainable, long-term value for our shareholders." Q2 2026 Year-over-year Operating Results Stockholder Value Q3 and Full-year 2026 Outlook "We delivered adjusted earnings per share near the midpoint of our guidance, reflecting our ongoing focus on profitability and disciplined execution," said Chelsea Lantz, interim chief financial officer. "Based on our first-half performance and outlook for the rest of the year, we are updating our annual guidance to revenue of $1.28 billion to $1.35 billion and adjusted earnings per share of $0.70 to $0.90. For the third quarter, we expect revenue between $310 million and $340 million, with adjusted earnings per share in the range of $0.10 to $0.20." Conference Call The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Aug. 24, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories. Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, initiatives, shareholder value, Prysm launch and its timing, and India expansion; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "become," "drive," "project," "outlook," "guidance," "will," "would," "could," "may," "might," the negative of these words and other similar words. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following: any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis; risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events; economic conditions and events globally; the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; competitive pressures in the company’s markets; risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business; adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others; political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets; uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results; risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations; uncertainties regarding the future financial performance of the businesses the company has acquired; risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements. The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law. Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period. Earnings per share, operating margin, and income tax rate, each excluding impairment charges, tax charges, and/or other charges, also are non-GAAP financial measures. Impairment charges and the tax charge incurred in the second quarter of 2026 are not part of the ongoing operations of our underlying business; and The other charges incurred in connection with certain corporate actions, as described in the footnotes to the non-GAAP reconciliation tables below, are not part of our ongoing operations. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below. The following table sets forth revenue for the three-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands): The following table sets forth revenue for the six-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands): The following tables provide information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended June 30, 2026 and 2025. "Customers" are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our salesforce who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force. "Paid Affiliates" are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as "Brand Affiliates" because their primary role is to promote our brand and products through their personal social networks. "Sales Leaders" are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter. (1) Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units. (2) We are currently anticipating other charges for the third quarter of 2026 of approximately $5 million in cash-based transition cost. Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. View source version on businesswire.com: https://www.businesswire.com/news/home/20260810531294/en/ Contacts Media: [email protected], (801) 345-6397Investors: [email protected], (801) 345-3577

e.l.f. Beauty, Inc. ELF posted fourth-quarter fiscal 2026 results, wherein both the top and bottom lines beat estimates. The top line increased year over year, while the adjusted EPS declined compared to the prior-year period. ELF posted adjusted earnings of 32 cents per share, down 59% from 78 cents a year ago. The figure beat the Zacks Consensus Estimate of 29 cents. e.l.f. Beauty price-consensus-eps-surprise-chart | e.l.f. Beauty Quote Net sales of $449.3 million rose 35.1% year over year from $332.7 million and surpassed the Zacks Consensus mark of $426 million. The quarter’s sales increase was driven by growth in both retail and e-commerce channels, spanning the United States and international markets. The company highlighted that Rhode contributed $113 million in net sales during the fiscal fourth quarter, while organic net sales growth for the quarter was 1%. Gross profit increased to $326.5 million, up 37.7% year over year from $237 million. Gross margin improved about 140 basis points year over year to 73% in the fiscal fourth quarter. The company cited pricing benefits as the primary tailwind, while also flagging higher tariffs as a partial offset. Adjusted selling, general and administrative expenses increased significantly by 73.1% year over year to $300 million from $173.3 million. The increase is primarily due to higher marketing, merchandising and distribution costs, compensation and benefits, depreciation and amortization, professional fees and regulatory fees. The company reported adjusted EBITDA of $58.8 million, down 27.7% year over year from $81.4 million in the prior-year period. Adjusted EBITDA margin declined to 13% of net sales, indicating pressure on overall profitability during the period. Cash and cash equivalents were $289.7 million as of March 31, 2026, while total debt was $841.7 million compared with $148.7 million of cash and $256.7 million of debt a year earlier. The balance sheet expansion reflects the financing and balance-sheet mechanics associated with the Rhode acquisition. Cash generation from operations was $212.5 million for fiscal 2026. The Zacks Rank #3 (Hold) company guided fiscal 2027 net sales in the range of $1,835-$1,865 million, implying expected growth of 12-14% year over year, with expected organic sales growth of 4-5% year over year. The company also projected adjusted EBITDA of $379-$385 million and adjusted net income of $198-$201 million. The earnings presentation further outlined an expected gross margin level of 71% and a tariff outlook of roughly 35% for fiscal 2027, along with marketing and digital investment targeted at 23-25% of net sales, keeping the focus on balancing growth with margin management. The company’s shares have lost 43.7% in the past three months compared with the industry’s decline of 32.3%. Image Source: Zacks Investment Research Some better-ranked stocks have been discussed below: The Estée Lauder Companies Inc. EL manufactures, markets, and sells skin care, makeup, fragrance, and hair care products worldwide.  At present, EL sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for EL’s current fiscal-year sales and earnings indicates growth of 4.5% and 59.6%, respectively, from the year-ago figures. EL delivered a trailing four-quarter earnings surprise of 39.1%, on average. Nu Skin Enterprises, Inc. NUS engages in the development and distribution of various beauty and wellness products worldwide. At present, NUS carries a Zacks Rank of 2 (Buy). The Zacks Consensus Estimate for NUS’ current fiscal-year sales and earnings implies a decline of 4% and 21.3%, respectively, from the year-ago figures. NUS delivered a trailing four-quarter earnings surprise of 1.1%, on average. Interparfums, Inc. IPAR manufactures, markets, and distributes a range of fragrances and fragrance-related products in the United States and internationally. At present, the company holds a Zacks Rank of 2. The consensus estimate for Interparfums’ current fiscal-year sales and earnings implies a decline of 0.1% and 8%, respectively, from the year-ago figures. IPAR delivered a trailing four-quarter earnings surprise of 8%, on average. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Estee Lauder Companies Inc. (EL) : Free Stock Analysis Report Interparfums, Inc. (IPAR) : Free Stock Analysis Report Nu Skin Enterprises, Inc. (NUS) : Free Stock Analysis Report e.l.f. Beauty (ELF) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Nu Skin Enterprises, Inc.? Here are five stocks we like better. Nu Skin said Q1 2026 results were in line with expectations, with revenue of $320.6 million and adjusted EPS of $0.14. Management also maintained full-year guidance and expects second-quarter revenue of $330 million to $360 million and EPS of $0.15 to $0.25. Prysm iO is emerging as a key growth driver, with nearly 2 million scans from more than 30,000 devices since launch and signs of higher subscription activity. Nu Skin said the platform is helping boost engagement, though broader adoption will take time as sales leaders adjust their approach. Emerging markets remain a strategic focus, especially Latin America, mainland China and India. The company sees improving momentum in China and is preparing for a formal India launch later this year, while also continuing to invest in expansion and technology. 3 high yield stock ETFs that make any income portfolio better Nu Skin Enterprises (NYSE:NUS) reported first-quarter 2026 results that management said were in line with expectations, as the company continued to invest in its Prysm iO wellness platform and emerging-market expansion while navigating macroeconomic pressures on consumers and supply chains. President and CEO Ryan Napierski said the quarter reflected “continued progress” toward Nu Skin’s vision of becoming “the world’s leading intelligent beauty and wellness platform.” He pointed to the sales leader introduction of Prysm iO, sustained growth in Latin America and improving trends in mainland China tied to the rollout of the Tru Face anti-aging product line. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? 3 Mid Cap Dividend Growers Worth Buying At the same time, Napierski said some reporting segments remained under pressure from broader macroeconomic and industry dynamics. He noted improving brand affiliate confidence in several regions and year-over-year growth in new sales leaders exiting the quarter, which he described as indicators of “improving energy” around Nu Skin’s entrepreneurial opportunity and product innovations. Interim CFO Chelsea Lantz said Nu Skin generated first-quarter revenue of $320.6 million, within the company’s guidance range, including a 1% favorable foreign currency impact. GAAP earnings per share were $0.04, while adjusted earnings per share were $0.14, excluding costs related to the decision to wind down the company’s separate BeautyBio business and other charges. Adjusted EPS was also in line with guidance. → MercadoLibre Boldly Invests in Growth: Discount Deepens Adjusted gross margin was 67.9%, compared with 67.8% in the prior-year period. Within Nu Skin’s core business, gross margin improved 20 basis points to 76.9%, which Lantz attributed to operational efficiency initiatives and product mix optimization. Consolidated selling expense was 34.3% of revenue, up from 32.5% a year earlier. In the core Nu Skin business, selling expense rose to 40.5% from 38.7%, which management said was consistent with efforts to reward sales leader productivity through compensation plan enhancements. Lantz said the company expects core selling expense to remain around 40% as it supports sales leader engagement and top-line growth initiatives. → MP Materials Is Quietly Building a Rare Earth Powerhouse General and administrative expenses declined by $9 million year over year on an adjusted basis. As a percentage of revenue, however, G&A rose to 29.9% from 28.9%, reflecting investments in technology and emerging market expansion, including India. Adjusted operating margin was 3.6%, down from 6.4% in the prior year. Napierski framed Prysm iO as one of Nu Skin’s two main growth drivers, alongside emerging-market expansion. The device enables users to conduct a 15-second fingertip scan and receive a wellness assessment across nutrition, fitness, lifestyle and supplementation, according to the company. Since Prysm iO’s initial introduction in December, Napierski said Nu Skin has generated nearly 2 million scans from more than 30,000 devices globally. He said the data is being combined with more than 20 million historical scans from the company’s BioPhotonic Scanner to improve wellness algorithms, assessment accuracy and product recommendations. Management said early indicators suggest the platform could help increase subscriptions. Napierski said subscription volume was up 5% year over year, while the percentage of subscribers to total customers was up 14%. He also said products certified to raise a user’s Prysm iO score are outperforming total product sales, and the company’s LifePak brand grew more than 10% year over year. Napierski cautioned that adoption will take time, saying sales leaders are transitioning from using Prysm primarily as a product demonstration tool to positioning it as a household wellness device. He said this shift carries “near-term switching costs” as sales leaders build new skills and move toward a more consultative role. In response to an analyst question, Napierski said the most successful early use cases have involved sales leaders positioning Prysm iO as part of a broader wellness assessment. He said training includes device and product education, guidance on the consumer journey, follow-up through customer relationship management tools and a “train-the-trainer” approach. Certifications are in place in multiple Asian markets, including Japan, Korea and China, and the company is working to extend those practices elsewhere. Nu Skin’s second major growth driver is expansion in developing and emerging markets, including Latin America, Southeast Asia, China and India. Napierski said Latin America remains an important growth region, supported by localized product solutions and refinements to the sales compensation structure designed to provide earlier rewards for product sales and team building. In mainland China, management cited continued improvement and growing leader engagement around the Tru Face anti-aging rollout. Napierski said the company also sees opportunities to scale its emerging-market model across Southeast Asia and additional parts of China. India remains a longer-term opportunity. Napierski said the company is in a pre-market entry phase and is working to solidify operations, infrastructure, manufacturing, quality, logistics, distribution and product formulas ahead of a planned formal launch by the end of the year. During the Q&A session, Napierski described India as “a very important mid to long-term market,” noting that the direct selling industry there is still relatively small but fast-growing. He said Nu Skin is not forecasting significant India revenue into its current guidance and views 2026 primarily as a learning period for that market. Lantz said Nu Skin completed a refinancing of its credit facilities during the quarter, extending maturities through 2031 and improving its cost of borrowing. Proceeds were used to repay existing debt. The company returned approximately $8 million to shareholders during the quarter, including $3 million in dividends and $5 million in share repurchases. Nu Skin ended the quarter with $137.3 million remaining under its share repurchase authorization. Asked about capital allocation, Lantz said the company’s priorities remain unchanged: funding the business, investing in strategic opportunities, maintaining liquidity and returning value to shareholders through dividends and buybacks as appropriate. She also said debt paydown remains a focus under the new facility. For the second quarter, Nu Skin expects: Revenue of $330 million to $360 million, assuming a relatively neutral foreign currency impact. Earnings per share of $0.15 to $0.25. Lantz said both metrics would represent sequential improvement from the first quarter. The company is maintaining its annual guidance and expects to provide more clarity after the second quarter. Management said it remains mindful of inflationary pressures and consumer sentiment risks tied to tariffs, fuel price increases and geopolitical conditions. Napierski said prolonged tariff and inflation pressures have affected raw materials, margins and consumers over time. Lantz added that Nu Skin is not currently anticipating a significant impact in its guidance model but is monitoring the situation and working on plans to mitigate risk. In closing remarks, Napierski said Nu Skin is encouraged by “green shoots” among sales leaders and by year-over-year growth in new sales leaders exiting the quarter, which he said supports the company’s plans to return to growth in the second half of the year. Nu Skin Enterprises, Inc is a Utah-based direct selling company that develops and distributes personal care products and dietary supplements. Operating through a network marketing model, Nu Skin offers a portfolio of wellness, anti-aging skin care, hair care and nutritional products designed to support healthy living and appearance. The company leverages independent distributors to market its offerings directly to consumers across multiple channels, including online platforms and localized events. Founded in 1984 by Blake M. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Nu Skin Enterprises Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for May 2026.